Brought to you by 
Proximagen partners again with Upsher-Smith in neurology
11 May 2022
Executive Summary
Upsher-Smith Laboratories Inc. (drug candidates for skin, CNS, cardiovascular, and women's health diseases) is teaming up with UK biotech Proximagen Neuroscience PLC for the second time. Upsher has now received exclusive North American rights to Proximagen's neuronal gap junction inhibitor tonabersat.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Proximagen partners again with Upsher-Smith in neurology
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice